To me, Dr. Frost's continued buying of OPK shares seems to be unrelated to the current intrinsic worth of this company. Someone smarter than me will have to ask him why he is buying these shares. If you look at eye care, Abbott just bough AMO, Bausch & Lomb was sold to private equity, Alcon is being bought by Novartis and now there are rumors that Allergan will be acquired. The demographics for eye care are terrific (baby boomers), but all of the above companies have many approved products and real revenue streams. I don't see these elements with OPK. Frost has thrown a lot of therapeutic concepts against the wall, I guess hoping that some of them work. That's the best I can do.
Drangles....I was heavily involved in IVAX way back then and I know that Frost was one of the best indicators on the stock. BUT...Ivax and Opko are completely different companies. IVAX had proved generic products....what does OPKO have?
Sample of Dr Frost buying-------------------- Insider buying hits 8-year low in '03 Some CEOs rewarded for loading up in a rising market By Matt Andrejczak, CBS.MarketWatch.com Last update: 2:08 p.m. EST Jan. 8, 2004 WASHINGTON (CBS.MW) -- Ivax Chairman and CEO Phillip Frost considers himself an impulsive buyer of his Miami-based company's shares, and he pulled the trigger in a big way in 2003. Frost bought 880,000 shares of the generic drug maker, making him one of the biggest insider buyers among CEOs. His bet paid off -- the company's shares (IVX:IVX News , chart , profile , more Last:
Delayed quote dataAdd to portfolio Analyst Create alert Insider Discuss Financials Sponsored by: IVX, , ) soared 96.7 percent in 2003. Frost was one of only a small number of corporate insiders who put their money where their faith was last year -- despite the bull market's return. Corporate insiders bought $1.1 billion of stock -- the lowest annual level 1995, according to Thomson Financial data.